CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤解析
英文原题：Multiple Myeloma Unpacked.
查看英文原题
Multiple Myeloma Unpacked.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）是一种以骨髓中浆细胞克隆性增殖为特征的血液系统恶性肿瘤。目前多发性骨髓瘤的治疗格局包括蛋白酶体抑制剂、免疫调节药物、单克隆抗体和自体干细胞移植的联合应用，近年来这些治疗手段显著改善了生存结局。然而，该疾病仍然具有挑战性，尤其是在复发/难治性病例中。正在进行的临床试验正在评估新的治疗选择，包括CAR-T 细胞疗法、双特异性抗体、抗体药物偶联物以及Cereblon E3连接酶调节药物等新型药物。本综述总结了MM的关键诊断标准、预后特征、疗效评估，并重点介绍了当前的治疗格局。
展开英文摘要原文
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. The current treatment landscape for multiple myeloma involves a combination of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation, which have significantly improved survival outcomes in recent years.
However, the disease remains challenging, particularly in relapsed and refractory cases. Ongoing clinical trials are evaluating new therapeutic options, including chimeric antigen receptor T cell therapy, bispecific antibodies, antibody drug conjugate and novel agents like Cereblon E3 Ligase Modulatory Drugs. This review summarizes the key diagnostic criteria, prognostic features, response assessment for MM and highlights the current treatment landscape.
论文信息
- 作者
- Gay F、Marchetti E、Bertuglia G
- 单位
- Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health Science, University of Torino, Torino, Italy.Italy
- 文献类型
- 综述
- 期刊
- Hematological oncology2025 Jun
- 原文标识
- PubMed 40517540 · DOI 10.1002/hon.70067
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →